Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19020372 | 1.00 | KDM1A (0.41) | KDM1APAOXSIGMAR1CHRNA7MC4R | |
| SCHEMBL81189 | 0.94 | — | — | |
| SCHEMBL14524205 | 0.94 | CHRNA7 (0.41) | PAOXSIGMAR1CHRNA7MC4RALDH1A1 | |
| SCHEMBL6662807 | 0.94 | CHRNA7 (0.41) | PAOXSIGMAR1CHRNA7MC4RALDH1A1 | |
| SCHEMBL17616057 | 0.94 | CHRNA7 (0.41) | PAOXSIGMAR1CHRNA7MC4RALDH1A1 | |
| SCHEMBL2323195 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL28585027 | 0.91 | CHRNA7 (0.39) | PAOXSIGMAR1CHRNA7MC4RALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL4938560 | 0.91 | CHRNA7 (0.39) | PAOXSIGMAR1CHRNA7MC4RALDH1A1 | |
| SCHEMBL6661360 | 0.91 | KDM1A (0.45) | KDM1ASIGMAR1CHRNA7ALDH1A1ALOX15 | |
| SCHEMBL6143515 | 0.87 | PAOX (0.46) | KDM1APAOXSIGMAR1MC4RALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913710-B2 | Benzene disulfonamide for the treatment of cancer | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913710-B2 | Benzene disulfonamide for the treatment of cancer | DUSP6, DUSP26, RASSF2 | KDM1A 3798/4885PAOX 2059/4885SIGMAR1 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.